News | October 06, 2024
Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
India has taken the lead in recognising NAFLD as a major non-communicable disease
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Subscribe To Our Newsletter & Stay Updated
